BPI fold containing family A member 1Genealiases: LUNX · NASG · PLUNC · SPLUNC1 · SPURT · bA49G10.5
Q-omics provides the consensus-scored BPIFA1 profile across patient tissues and cancer cell-line models. BPIFA1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, BPIFA1 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, BPIFA1 RNA expression shows 7,224 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, LUSC, and TGCT as cancer lineages where BPIFA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFA1 survival associations across molecular data types. BPIFA1 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFA1 RNA expression–survival associations across cancer types. High BPIFA1 expression shows unfavorable associations in DLBC, MESO, READ and OV, but favorable associations in LUSC and LGG. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for BPIFA1 RNA expression.
This table summarizes BPIFA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for BPIFA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFA1 shows lower tumor expression in LUSC and HNSC and higher tumor expression in LUAD, THCA and LUSC. The LUSC box plot shows higher BPIFA1 RNA expression in normal versus tumor tissue (log2 FC = −2.316, t-test p = .028).
This table shows molecular features associated with BPIFA1 in patient tissues and cancer cell lines. In patient samples, BPIFA1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BPIFA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SKIN.
